| Epidemiology | Lifetime | 138 | US 73 | 99.82 |
| Immunology | Lifetime | 79 | US 51 | 99.87 |
| Infectious Diseases | Lifetime | 287 | US 149 | 98.96 |
| Management, Monitoring, Policy and Law | Lifetime | 983 | US 277 | 96.10 |
| Immunology | 2021-2025 | 112 | US 40 | 97.77 |
| Epidemiology | 2021-2025 | 389 | US 129 | 96.75 |
| Infectious Diseases | 2021-2025 | 482 | US 187 | 89.75 |
| Genetics | 2021-2025 | 603 | US 223 | 82.50 |
| Mycobacterium research and diagnosis | Lifetime | 4 | US 2 | 99.91 |
| Immunodeficiency and Autoimmune Disorders | Lifetime | 4 | US 3 | 99.96 |
| Blood disorders and treatments | Lifetime | 2 | US 2 | 99.90 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | Lifetime | 5 | US 3 | 99.84 |
| Tuberculosis Research and Epidemiology | Lifetime | 44 | US 21 | 99.71 |
| Immune Cell Function and Interaction | Lifetime | 270 | US 159 | 99.63 |
| Cytokine Signaling Pathways and Interactions | Lifetime | 87 | US 44 | 99.32 |
| Antifungal resistance and susceptibility | Lifetime | 130 | US 60 | 99.20 |
| Immune Response and Inflammation | Lifetime | 402 | US 192 | 98.97 |
| Infectious Diseases and Mycology | Lifetime | 95 | US 41 | 98.37 |
| Fungal Infections and Studies | Lifetime | 186 | US 87 | 98.65 |
| Quinazolinone synthesis and applications | Lifetime | 199 | US 41 | 95.79 |
| Inflammasome and immune disorders | Lifetime | 475 | US 137 | 95.80 |
| Recreation, Leisure, Wilderness Management | Lifetime | 101 | US 52 | 97.15 |
| Infectious Diseases and Tuberculosis | Lifetime | 623 | US 188 | 95.42 |
| Diverse Aspects of Tourism Research | Lifetime | 486 | US 103 | 97.15 |
| Pneumocystis jirovecii pneumonia detection and treatment | Lifetime | 852 | US 355 | 96.12 |
| Cystic Fibrosis Research Advances | Lifetime | 724 | US 290 | 95.09 |
| Hematological disorders and diagnostics | Lifetime | 746 | US 330 | 91.68 |
| Autoimmune and Inflammatory Disorders | Lifetime | 669 | US 203 | 91.19 |
| Sarcoidosis and Beryllium Toxicity Research | Lifetime | 805 | US 280 | 91.10 |
| Actinomycetales infections and treatment | Lifetime | 233 | US 55 | 89.34 |
| Legionella and Acanthamoeba research | Lifetime | 400 | US 143 | 90.53 |
| Immune responses and vaccinations | Lifetime | 635 | US 209 | 85.64 |
| Place Attachment and Urban Studies | Lifetime | 211 | US 79 | 87.23 |
| Burkholderia infections and melioidosis | Lifetime | 487 | US 96 | 80.13 |
| Adventure Sports and Sensation Seeking | Lifetime | 669 | US 186 | 73.38 |
| Immunodeficiency and Autoimmune Disorders | 2021-2025 | 29 | US 10 | 99.00 |
| Blood disorders and treatments | 2021-2025 | 28 | US 12 | 96.31 |
| Mycobacterium research and diagnosis | 2021-2025 | 128 | US 31 | 95.02 |
| Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 2021-2025 | 139 | US 35 | 89.19 |
| Fungal Infections and Studies | 2021-2025 | 353 | US 99 | 91.09 |
| Tuberculosis Research and Epidemiology | 2021-2025 | 852 | US 176 | 89.98 |
| Antifungal resistance and susceptibility | 2021-2025 | 682 | US 160 | 87.89 |
| Parvovirus B19 Infection Studies | 2021-2025 | 240 | US 70 | 78.65 |
| Adrenal Hormones and Disorders | 2021-2025 | 755 | US 102 | 68.40 |
| Actinomycetales infections and treatment | 2021-2025 | 143 | US 22 | 60.46 |
| Quinazolinone synthesis and applications | 2021-2025 | 703 | US 36 | 59.56 |